Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis

Abstract

Cyclooxygenase-2 (COX-2) has been implicated in a variety of human malignancies and, accordingly, COX-2 selective inhibitors are being investigated as important chemopreventive and therapeutic agents. How COX-2 overexpression results in tumorigenesis and how COX-2 selective agents mediate their chemopreventive effects are issues that remain poorly understood. Here we report that the tumor suppressor p53 upregulates COX-2 expression and that COX-2 can in turn inhibit p53-dependent transcription. Additionally, a COX-2-selective inhibitor potentiates p53-induced apoptosis, which also supports the notion that COX-2 activity appears to interfere with p53 function. Expression of exogenous COX-2 in p53 wild-type cells does not affect the cytoplasmic or nuclear levels of p53, suggesting that COX-2 may not affect p53 turnover or subcellular localization. We further demonstrate that endogenous COX-2 interacts with p53 and that COX-2 and p53 interactions are a physiologically relevant event. Thus, p53 upregulates COX-2 and COX-2 in turn appears to negatively affect p53 activity via mechanisms that could involve physical interactions between COX-2 and p53. Based on our results, we propose that p53-dependent upregulation and activation of COX-2 appear to be yet another novel mechanism by which p53 could abate its own growth-inhibitory and apoptotic effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Alarcon-Vargas D and Ronai Z . (2002). Carcinogenesis, 23, 541–547.

  • Corcoran CA, Huang Y and Sheikh MS . (2004). Cancer Biol. Ther., 3, 721–725.

  • Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H and Dixit VM . (2004). Nature, 429, 86–92.

  • Gallo O, Schiavone N, Papucci L, Sardi I, Magnelli L, Franchi A, Masini E and Capaccioli S . (2003). Am. J. Pathol., 163, 723–732.

  • Giaccia AJ and Kastan MB . (1998). Genes Dev., 12, 2973–2983.

  • Grewal S, Ponnambalam S and Walker JH . (2003). J. Cell. Sci., 116, 2303–2310.

  • Grosch S, Tegeder I, Niederberger E, Brautigam L and Geisslinger G . (2001). FASEB J., 15, 2742–2744.

  • Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L and Chittenden T . (2001). Proc. Natl. Acad. Sci. USA, 98, 11318–11323.

  • Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, Aaronson SA and Lee SW . (2002). EMBO J., 21, 5635–5644.

  • Hofseth LJ, Hussain SP and Harris CC . (2004). Trends Pharmacol. Sci., 25, 177–181.

  • Huang Y, He Q, Hillman MJ, Rong R and Sheikh MS . (2001). Cancer Res., 61, 6918–6924.

  • Jones DA, Carlton DP, McIntyre TM, Zimmerman GA and Prescott SM . (1993). J. Biol. Chem., 268, 9049–9054.

  • Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ and Chen CS . (2004). Cancer Res., 64, 1444–1451.

  • Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R and Benchimol S . (2003). Cell, 112, 779–791.

  • Liou JY, Deng WG, Gilroy DW, Shyue SK and Wu KK . (2001). J. Biol. Chem., 276, 34975–34982.

  • Lloyd DR and Hanawalt PC . (2002). Cancer Res., 62, 5288–5294.

  • Luo X, Huang Y and Sheikh MS . (2003). Oncogene, 22, 7247–7257.

  • Majumder M, Ghosh AK, Steele R, Ray R and Ray RB . (2001). J. Virol., 75, 1401–1407.

  • Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL and Smith WL . (1995). J. Biol. Chem., 270, 10902–10908.

  • Nakano K and Vousden KH . (2001). Mol. Cell, 7, 683–694.

  • Nikolaev AY, Li M, Puskas N, Qin J and Gu W . (2003). Cell, 112, 29–40.

  • Seo YR, Fishel ML, Amundson S, Kelley MR and Smith ML . (2002). Oncogene, 21, 731–737.

  • Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace Jr AJ and el-Deiry WS . (1998). Cancer Res., 58, 1593–1598.

  • Sheikh MS and Fornace Jr AJ . (2000). J. Cell Physiol., 182, 171–181.

  • Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM and Lippman SM . (2001). Cancer Res., 61, 4879–4884.

  • Smigel K . (2000). J. Natl. Cancer Inst., 92, 297–299.

  • Spencer AG, Woods JW, Arakawa T, Singer II and Smith WL . (1998). J. Biol. Chem., 273, 9886–9893.

  • Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A and Dannenberg AJ . (1999). J. Biol. Chem., 274, 10911–10915.

  • Swamy MV, Herzog CR and Rao CV . (2003). Cancer Res., 63, 5239–5242.

  • Thun MJ, Henley SJ and Partrono C . (2002). J. Natl. Cancer Inst., 94, 252–266.

  • Trifan OC, Smith RM, Thompson BD and Hla T . (1999). J. Biol. Chem., 274, 34141–34147.

  • Wang W and El-Deiry WS . (2003). Cancer Biol. Ther., 2, 196–202.

  • Williams CS, Mann M and DuBois RN . (1999). Oncogene, 18, 7908–7916.

  • Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B . (2001). Mol. Cell, 7, 673–682.

  • Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW and Vogelstein B . (1999). Proc. Natl. Acad. Sci. USA, 96, 14517–14522.

Download references

Acknowledgements

We thank Dr Bert Vogelstein for providing the p53-inducible DLD1 human colon cancer cells as well as pCMV-p53 and PG13-Luc constructs. We thank Dr Richard Kulmacz for providing us with the pSG5-COX-2 expression vector. Also, we thank Dr Thomas Chittenden for providing us with pGL3-PUMA promoter construct. This work was supported in part by the National Institutes of Health Grants CA105300, CA086945 and United States Army PCRP Grant PC030519.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Saeed Sheikh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corcoran, C., He, Q., Huang, Y. et al. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 24, 1634–1640 (2005). https://doi.org/10.1038/sj.onc.1208353

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208353

Keywords

This article is cited by

Search

Quick links